Neuphoria Therapeutics (NEUP) Price to FCF (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported Price to FCF for 4 consecutive years, with 150.58 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Price to FCF fell 340.18% year-over-year to 150.58 in Q1 2026; TTM through Mar 2026 was 29.56, a 102.68% decrease from a year earlier, with the FY2025 full-year figure at 8796.17, up 11429.73% from the prior year.
• Price to FCF was 150.58 for Q1 2026 at Neuphoria Therapeutics, down from 75.22 in the prior quarter.
• Over five years, Price to FCF peaked at 62.69 in Q1 2025 and troughed at 911.79 in Q3 2023.
• A 4-year average of 308.67 and a median of 248.46 in 2025 frame the typical range for Price to FCF.
• Across the five-year window, Price to FCF jumped 113.41% in 2025 and sank 340.18% in 2026, its largest moves.
• Over 4 years, Price to FCF stood at 561.19 in 2023, then surged by 77.31% to 127.33 in 2024, then jumped by 40.93% to 75.22 in 2025, then tumbled by 100.19% to 150.58 in 2026.
• The last three Price to FCF figures came in at 150.58 (Q1 2026), 75.22 (Q4 2025), and 386.78 (Q3 2025), per Business Quant data.